Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

NCT04745234 is registered in ClinicalTrials.gov with Kyowa Kirin, Inc. as lead sponsor.

NCT NCT04745234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04745234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
Lead sponsor
Kyowa Kirin, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
August 16, 2021
Completion date
May 31, 2025
Enrollment
34 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma refractory, cutaneous t-cell lymphoma, relapsed